Thanks for the link.
This as you know doesn't involve leronlimab but rather straight allogenic immunity. To me it just shows that our guys in the article are good doctor/researchers after a cure for HIV, going wherever their work leads them.
But since we can't practically speaking do marrow transplants on the millions of HIV patients in the world, that leaves long-acting leronlimab and AAV-delivered leronlimab still very much in the running.